Lakefront Biotherapeutics (GLPGF) Cash from Investing Activities Growth (5y) (2021 - 2026)
Powered by 
Analysis
Lakefront Biotherapeutics (GLPGF) Cash from Investing Activities Growth (5y) (2021 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 211.51 Bn | 197.52 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 181.48 Bn | 178.30 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 132.45 Bn | 124.60 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 82.87 Bn | 74.88 Bn | 3.93 Bn |
| 5 | Argenx Se | 61.59 Bn | 56.41 Bn | 1.37 Bn |
| 6 | Moderna | 54.72 Bn | 49.59 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.13 Bn | 30.82 Bn | 992.69 Mn |
| 8 | Biogen | 31.29 Bn | 30.01 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 30.31 Bn | 30.31 Bn | 1.16 Mn |
| 10 | Lakefront Biotherapeutics | 1.73 Bn | 1.73 Bn | 3.51 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | -34.63% |
| Jun 30, 2025 | 18.68% |
| Mar 31, 2025 | -38.66% |
| Dec 31, 2024 | 15.07% |
| Sep 30, 2024 | 42.74% |
| Jun 30, 2024 | 69.57% |
| Mar 31, 2024 | 59.57% |
| Dec 31, 2023 | 45.52% |
| Mar 31, 2023 | -177.56% |
| Dec 31, 2022 | -355.73% |
| Mar 31, 2022 | -182.80% |
| Jun 30, 2021 | 151.33% |
| Mar 31, 2021 | 249.65% |